147 related articles for article (PubMed ID: 17291620)
1. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate.
Lee DY; Kim SK; Kim YS; Son DH; Nam JH; Kim IS; Park RW; Kim SY; Byun Y
J Control Release; 2007 Apr; 118(3):310-7. PubMed ID: 17291620
[TBL] [Abstract][Full Text] [Related]
2. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
3. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
Lee DY; Park K; Kim SK; Park RW; Kwon IC; Kim SY; Byun Y
Clin Cancer Res; 2008 May; 14(9):2841-9. PubMed ID: 18451252
[TBL] [Abstract][Full Text] [Related]
4. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
Hwang SR; Seo DH; Al-Hilal TA; Jeon OC; Kang JH; Kim SH; Kim HS; Chang YT; Kang YM; Yang VC; Byun Y
J Control Release; 2012 Nov; 163(3):374-84. PubMed ID: 23041275
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
6. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
7. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.
Lee DY; Lee SW; Kim SK; Lee M; Chang HW; Moon HT; Byun Y; Kim SY
Pharm Res; 2009 Dec; 26(12):2667-76. PubMed ID: 19830530
[TBL] [Abstract][Full Text] [Related]
10. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
16. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor gamma.
Tsuzuki T; Kawakami Y
Carcinogenesis; 2008 Apr; 29(4):797-806. PubMed ID: 18174233
[TBL] [Abstract][Full Text] [Related]
19. Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles.
Khatun Z; Nurunnabi M; Cho KJ; Lee YK
Carbohydr Polym; 2012 Nov; 90(4):1461-8. PubMed ID: 22944403
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]